HCC | Clinical

Regorafenib/Nivolumab Proof of Concept Suggested in Third-Line, Refractory HCC

March 28, 2021

Half of all patients with hepatocellular carcinoma treated with the combination of regorafenib and nivolumab following progression on 2 lines of chemotherapy achieved disease control, according to initial results from a phase 2 proof-of-concept trial.

Sintilimab With SBRT Leads to 100% Disease Control in Oligometastatic HCC

March 25, 2021

In a single-arm study, 100% of patients treated with sintilimab plus stereotactic body radiotherapy who had oligometastases of hepatocellular carcinoma achieved disease control and were alive and progression free at 6 months.